Navigation Links
Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds

SUNNYVALE, Calif., April 11, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. announced today multiple presentations regarding its novel histone deacetylase (HDAC) inhibitor and Bruton's tyrosine kinase inhibitor compounds. The presentations will take place at the American Association for Cancer Research (AACR) 2007 Annual Meeting being held April 14-18, 2007, at the Los Angeles Convention Center, in Los Angeles, CA.

    The presentations are as follows:


    Sunday, April 15, 2007

    Session: HDAC Inhibitors 1

    Poster Presentation: Mechanisms of sensitivity in primary hematopoietic

    tumors and tumor lines to a novel HDAC inhibitor PCI-24781

    Abstract #678:  8:00 a.m. -12:00 p.m.

    Presenter:  Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc.


    Session: HDAC Inhibitors 1

    Poster Presentation: Radiosensitization by the HDAC inhibitor PCI-24781 in

    SiHa and WiDr human tumor cell lines

    Abstract #695:  8:00 a.m. -12:00 p.m.

    Presenter:  Peggy L. Olive, Ph.D., British Columbia Cancer Research Center


    Monday, April 16, 2007

    Session: Targeted Agents and Other Novel Therapies

    Poster Presentation: Identification of cross-validated functional

    biomarkers for a novel HDAC inhibitor PCI-24781, and their utility for

    selection of clinical indications

    Abstract #1830:  8:00 a.m. -12:00 p.m.

    Presenter:  Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc.


    Session: DNA Repair and Chemotherapeutic Agent Resistance

    Poster Presentation: Novel histone deacetylase (HDAC) inhibitor PCI-24781

    disrupts RAD51 foci and inhibits homologous recombination

    Abstract #1966:  8:00 a.m. -12:00 p.m.

    Presenter:  Shanthi Adimoolam, Ph.D., Pharmacyclics, Inc.


    Wednesday, April 18, 2007

    Session: Kinases 1

    Poster Presentation: PCI-31523: An irreversible inhibitor of Bruton's

    tyrosine kinase (Btk) that disrupts B cell receptor (BCR) signaling, is

    cytotoxic to B cell lympho
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
3. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
4. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/23/2014)... , Sept. 23, 2014 Research ... the "Physician Office Laboratory Markets, 3rd Edition" ... This report, Physician Office Laboratory Markets is Kalorama,s ... IVD industry. Physician office laboratories are diverse in ... perform reimbursable, in-office pregnancy and glucose tests. Some ...
(Date:9/23/2014)... DUBLIN , September 23, 2014 /PRNewswire/ ... ) has announced the addition of the  ...  report to their offering.  ... injectable drug delivery market holds significant potential ... with vials and painful needles to the ...
(Date:9/23/2014)... -- SiteOne Therapeutics Inc. today announced the completion of its ... Management and Biobrit LLC, with additional investors Mission Bay ... financing positions SiteOne to advance its oral Na V ... its technology platform for long-acting local analgesics, pain diagnostics ... the financing, Lowell Sears (Sears Capital Management) ...
Breaking Medicine Technology:Physician Office Laboratory Markets, 3rd Edition 2Physician Office Laboratory Markets, 3rd Edition 3Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3
... 3 Australian researchers have developed gene expression ... colorectal growths from non-cancerous controls. , , ... conference in Chicago, the preliminary findings are the ... Flinders University and Australian healthcare company, Clinical Genomics ...
... Day 3 And All Subsequent Study Visits - , ... Pharma Co., Ltd., (DSP) announced today that positive results from ... of patients with schizophrenia have been published in The ... placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated a ...
Cached Medicine Technology:Advance in Bowel Cancer Test Research 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 3Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 4
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- Both drinking ... risk factors for alcohol abuse by high school students, ... a survey of high school students who drink, could ... those who already drink, to stop them from becoming ... distinguish between age of first alcohol use and progression ...
(Date:9/23/2014)... Grinnell Mutual seeks submissions from ... the Midwest. Working Together Making It Better will ... with projects positively impacting their communities. , “So ... their communities a better places,” said Grinnell ... Barb Baker. “Their leadership—as coaches, as volunteers, as ...
(Date:9/23/2014)... CORVALLIS, Ore. A recent Oregon survey about an ... into the daily routine of elementary school students found ... students and teachers, and offered clear advantages for overly ... was developed and produced by the Healthy Youth Program ... and is available nationally. , Brain Breaks leads children ...
(Date:9/23/2014)... BC (PRWEB) September 23, 2014 Vancouver ... will now be offering commercial electrical services in Vancouver, ... of operations; whether it is a small maintenance project ... personalize its solution package to meet the needs of ... that the services will be of an affordable price. ...
(Date:9/23/2014)... 2014 SOURCE: Solutions from Our ... were made to Rimidi Diabetes and ... with business solutions to challenges faced by patients and ... collaboration between The Hitachi Foundation, Village ... entrepreneurs with the investment capital, mentoring, and support needed ...
Breaking Medicine News(10 mins):Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5
... Research &,Design Journal (HERD) is an interdisciplinary, peer-reviewed, ... and practice of,evidence-based healthcare design by disseminating research ... practice. The,vision of HERD is to improve healthcare ... those receiving and giving care., HERD is ...
... IL, April 10, 2008 The American Pain Society (APS), ... second annual Clinical Centers of Excellence in Pain Management ... Six multidisciplinary pain programs were recognized. They are: ... Pain Management Center, Lebanon, NH , ...
... Spanish . , The removal through endoscopy of ... oesophagus can avoid complete extirpation of this part of ... University Hospital of Navarra for the last three years, ... Endoscopy in the Digestive System, organized by the Digestive ...
... then a research team from the University of Reading and ... may have good news for you. , They have found ... age-related deficits in memory, according to a study soon to ... Medicine. The researchers working at the Schools of Food ...
... 10 - Entries for the eighth,annual Michael E. ... Research (FBR) and named after FBR,s chairman, are ... all professional journalists whose reporting,has enhanced public understanding ... humane and responsible use of animal models., ...
... ... Network, STAMFORD, Conn., April ... lower middle-market special situation,and deep value investments, announced today that it has ... with a commitment from funds managed by the investment management,arm of a ...
Cached Medicine News:Health News:The Center for Health Design & Vendome Group Unveil Premiere Issue of Health Environments Research & Design Journal (HERD) - http://www.herdjournal.com 2Health News:American Pain Society announces recipients of Clinical Centers of Excellence Awards 2Health News:American Pain Society announces recipients of Clinical Centers of Excellence Awards 3Health News:Removal of superficial tumors in esophagus by endoscopy can avoid extirpation of this part 2Health News:Removal of superficial tumors in esophagus by endoscopy can avoid extirpation of this part 3Health News:Removal of superficial tumors in esophagus by endoscopy can avoid extirpation of this part 4Health News:Getting forgetful? Then blueberries may hold the key 2Health News:DeBakey Awards to Recognize Excellence in Biomedical Research Journalism 2Health News:Atlantic Street Capital Announces First Close 2
... nebulizers offer a spill-proof design and effective ... 45° angle. All medical nebulizers are free-standing ... of configurations are available., ,All Portex® ... ,Portex® medication nebulizers feature consistently fine misting ...
... nebulizers offer a spill-proof design and effective ... 45° angle. All medical nebulizers are free-standing ... of configurations are available., ,All Portex® ... ,Portex® medication nebulizers feature consistently fine misting ...
... This convenient, procedural kit contains everything ... the methacholine challenge test quickly and efficiently: ... gas supply tubing, syringe and needle., ... available in the European Community., ,Intended ...
... Hand Held Nebulizer can be held at angles ... has a built in spill column, finger grooves ... medication setups and 7 feet of regular oxygen ... maintain small particle size and sustain optimum mist ...
Medicine Products: